The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

There are many purposes that spots and stripes serve in nature, but how they form has been more of a mystery to scientists.

In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

Abstract: Graph scattering transform (GST) is mathematically-designed graph convolutional model that iteratively applies graph filter banks to achieve comprehensive feature extraction from graph ...

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...

Abstract: Currently, brain and social networks are examples of new data types that are massively acquired and disseminated [1]. These networks typically consist of vertices (nodes) and edges ...